30% MDT trim at ~$87.50 on confirmed 200 SMA breakdown; retain 70% core anchored at $92.00 stop with Q2 FY27 re-evaluation
Process-correct, payoff-calibrated Underweight that activates on confirmed momentum breakdown (200 SMA broken on 3x volume), sizes to meaningful downside protection (30% trim) without full exit, anchors the 70% retained core to a structurally valid $92.00 stop (2.3 ATR) with room for normal volatility relief bounces, and preserves directional optionality around the binary Q2 FY27 catalyst — explicitly absorbing prior Hold streak losses (-0.2% to -2.5% alpha from delayed confirmation), prior Underweight undersizing (20-25% was payoff-capped), and analyst disagreements on magnitude while synthesizing the correct elements from each.
| Position | Action |
|---|---|
| Immediate (Day 1) | Execute 30% trim at market (~$87.50) — pre-committed, no discretion |
| Confirmed close below $85 on volume >12M | Auto-execute additional 15-20% (second tranche — 'cancel-and-flatten' architecture) |
| Close >$91.00 with MACD histogram contracting AND RSI >45 | Hard cancel of second tranche — bull trigger fires, flatten entirely |
| Q2 FY27 print: Revenue growth >8% YoY AND operating margin >19.5% | Bear thesis disproven; add 15-20% back to position |
| Q2 FY27 print: Revenue growth <5% YoY OR operating margin <18% | Complete exit of remaining position |
| Q2 FY27 print: RSI <30 AND MACD histogram printing higher low | Watch for reversal pattern before adding — technical basing scenario |
The technical panic represents institutional accumulation disguised as capitulation in a high-quality compounder with accelerating fundamentals, an imminent diabetes spin-off catalyst, and a dividend yield that provides a fundamental floor at a historically cheap multiple.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 89.38 | bearish |
| close_50_sma | 88.98 | bearish |
| close_200_sma | 87.29 | bearish |
| RSI(14) | 39.79 | bearish |
| MACD | -0.284 | bearish |
| MACD Signal | 0.35 | bearish |
| MACD Histogram | -0.631 | bearish |
| Bollinger Middle (20 SMA) | 90.81 | bearish |
| Bollinger Lower Band | 87.30 | bearish |
| ATR(14) | 2.13 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Execute 30% trim at market (~$87.50)
Q1 FY27 marked accelerating top-line growth and improving earnings outlook
↩ rebuts: “Fundamentals are deteriorating”
EV: +25% to +40% · concedes: Bear acknowledges technical signals are valid in the short term; No Fed rate cuts expected (96% probability) in 2026; 30-year Treasury at multi-decade highs with mortgages at 7.58%; Bear case targets $52.81 if no recovery occurs (-39%)
MDT is a value trap: a slow-decline, capital-intensive, goodwill-heavy, low-growth healthcare conglomerate losing share to nimbler competitors, with a deteriorating technical setup, hostile macro environment, and no near-term catalysts to drive re-rating.
EV: -$8 to -$9 from entry (target $78-82) · concedes: Q1 FY27 revenue growth of 13.7% is the strongest in years — acknowledged as bull's 'strongest card'; Dividend yield of 3.22% and FCF coverage of 1.6x are factually accurate; Goodwill and intangibles of $43.2B are real assets (though bear views them as risk, not value); The 200 SMA 'test' framing as capitulation has some historical precedent (June 18, 2026 example); Spin-off data cited (3-5% outperformance for new entities) is accurate academic literature, just misapplied by bulls to wrong entity; UK recession probability data was sourced from bull's own macro report
→ vs conservative: Forward P/E of 13.6x is not cheap — it is based on $6.41 forward EPS that the actual sequential revenue decline from $9,807M to $9,756M in Q1 FY27 undermines in real time; this is a value trap, not a bargain
→ vs conservative: Conservative 'trim into bounces toward 89-90' is indecision and gets whipsawed every time the 50 SMA briefly acts as resistance before failing; structural breaks require reducing exposure on the breakdown, not trimming into strength
→ vs conservative: Operating margin compressed 170 basis points against an easy comp — they couldn't even expand margins when the bar was low, making the forward earnings estimate even less credible
→ vs neutral: 3.22% dividend yield with 0.57 beta is not a defensive safe haven in a 96% zero-cut environment with 30-year Treasury at post-2002 highs and mortgage rates at 7.58%; bond proxies get re-rated lower as long-duration yields rise
→ vs neutral: MMED spin-off with 7% exchange-offer discount is not a neutral corporate event — it indicates management knows MDT is overvalued relative to sum-of-parts or is dumping a high-multiple growth segment into an entity lacking MDT's defensive cash flow support
→ vs neutral: 'Wait for confirmation' is paralysis — the technical breakdown IS the confirmation, the earnings quality deterioration IS the confirmation, the macro regime IS the confirmation, the spin-off overhang IS the confirmation; the only thing left is price action
| Volume |
| 19,445,975 |
| bearish |
Support: 87.29 · 87.3 · 84 · 85 · 86 | Resistance: 88.98 · 89.38 · 90.81 · 91.5
MDT technical analysis as of 2026-09-29 shows a bearish breakdown: price at $87.09 closed below all three key moving averages (10 EMA 89.38, 50 SMA 88.98, 200 SMA 87.29) and violated the lower Bollinger Band at 87.30 on capitulation volume of 19.45M shares (~3× average). Momentum indicators are firmly bearish with MACD at -0.284 and histogram at -0.631 (multi-month low), while RSI at 39.79 suggests room to fall before oversold territory. Key support lies at 87.30 (200 SMA/Bollinger lower band zone) with next support at 84–85; resistance at 88.98 (50 SMA) and 89.38 (10 EMA). The recommendation is HOLD with bias to trim longs into bounces toward 89–90, avoiding new long positions until price reclaims the 50 SMA with confirming MACD improvement.
Market Cap
$111.4B
P/E (TTM)
21.45
Forward P/E
13.59
PEG Ratio
1.61
Price / Book
2.22
EPS (TTM)
$4.06
Forward EPS
$6.41
Dividend Yield
3.22%
Beta
0.574
52-Week High
$106.33
52-Week Low
$73.31
200-Day MA
$88.91
Revenue FY26
$36.36B
Revenue TTM
$37.54B
Q1 FY27 Revenue Growth
+13.7% YoY
Gross Margin
65.3%
Operating Margin
19.3%
Net Margin
13.9%
Net Income FY26
$4.80B
Diluted EPS FY26
$3.73
ROE
10.6%
ROA
5.1%
FCF (TTM)
$5.41B
FCF Yield
4.9%
OCF FY26
$7.33B
Dividends Paid FY26
$3.64B
Total Assets
$93.3B
Total Equity
$50.85B
Goodwill & Intangibles
$53.42B
Tangible Book Value
($3.19B)
Total Debt
$28.15B
Cash + ST Investments
$8.82B
Net Debt
$26.41B
Net Debt / Equity
0.53x
Net Debt / EBITDA
~2.5x
Current Ratio
2.07
Working Capital
$12.59B
Goodwill / Assets
46%
D&A FY26
$2,958M
CapEx Q1 FY27
$503M
M&A Spending (Q4 FY26+Q1 FY27)
$1.57B
Restructuring Charges FY26
$362M
Payout Ratio (FCF basis)
~63%
Buyback Yield
~1%
Strengths
Concerns
MDT is a high-quality, defensive medical device leader with accelerating fundamentals — Q1 FY27 revenue jumped +13.7% YoY, breaking from the prior ~3.6% growth trend, signaling that recent product launches (diabetes 780G pump, pulsed-field ablation, Hugo surgical robot, renal denervation) are driving meaningful top-line acceleration. The stock trades at an attractive forward P/E of 13.6x with a 3.22% dividend yield and ~4.9% FCF yield, though elevated goodwill ($53.42B, 57% of assets) and negative tangible book value create intangible risk, and ROE of 10.6% lags peer med-tech leaders. The recommendation is HOLD-to-BUY, with tactical investors advised to wait for Q2 FY27 confirmation of the acceleration trend before building positions.
Macro: The macro backdrop is predominantly negative for MDT: Polymarket prices 96% probability of no Fed cuts in 2026 ($8.67M volume), the 30-year Treasury hit its highest level since 2002 during the week, and mortgage rates climbed to 7.58% near a 3-year high. The equity tape is risk-off with Dow/S&P/Nasdaq all lower on September 28, while gold at $4,147.70 (+0.27%) and falling oil prices confirm a late-cycle/defensive hedging signature. USD strength is implied by the hawkish Fed posture, creating a headwind for MDT's ~40% non-US revenue. Recession odds remain low but rising (US: 8%, UK: 10%, Japan: 4%). FRED data (CPI, Fed Funds, 10Y yield) unavailable due to API configuration issue.